Lilly’s revenue soars 48%, driven by demand for its GLP-1s
Foundayo, its new GLP-1 pill, brought in $98 million in sales in the first full quarter since launching in April, coming in lower than the FactSet consensus of $103 million. Lilly has said for months that it expects most of Foundayo’s pickup to occur outside the U.